For this reason, there is growth pharmaceutical interest focuse on developing the cathepsin K inhibitors to control the bone resorption, although cathepsin K inhibitors have failed in osteoporosis clinical trials [7]. The gene discussed is CTSK; the disease is osteoporosis.